Ignite Creation Date:
2025-12-25 @ 12:33 AM
Ignite Modification Date:
2026-02-06 @ 8:57 AM
Study NCT ID:
NCT00681967
Status:
COMPLETED
Last Update Posted:
2010-09-23
First Post:
2008-05-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
Sponsor:
AstraZeneca
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Head and Neck Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | squamous cell cancer of the head & neck | View |
| None | Gefitinib | View |
| None | IRESSA | View |
| None | EGFR Inhibitor | View |
| None | EGFR-tyrosine kinase inhibitor | View |
| None | Subjects with histologically proven squamous cell cancer of the head … | View |
| None | Cohort 1:qualifying for postoperative radiotherapy | View |
| None | (pT3, pT4, pN2b, pN2c, pN3). | View |
| None | Cohort 2:qualifying for definite chemoradiotherapy | View |
| None | (Lateral oropharynx, tonsils: T1N2b-3, T2N1-3, T3any N; | View |
| None | Base of tongue, vallecula: T1N1-3, T2-4 any N; Oral cavity, | View |
| None | glottic and supraglottic larynx; Any TN1-3, T3-4 any N; | View |
| None | Hypopharynx: T1N1-3, T2-4 and N) | View |